Sponsors / NTLA
NTLA

Intellia Therapeutics

Company identity has not yet been verified

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
3Trials in this database
10Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)NCT06128629Intellia TherapeuticsPhase 3Recruiting2027-12Estimated
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)NCT06634420Intellia TherapeuticsPhase 3Active not recruiting2026-02-10Actual
A Phase 3 Study of NTLA-2001 in ATTRv-PNNCT06672237Intellia TherapeuticsPhase 3Recruiting2027-07Estimated

Latest recorded trial changes

A Phase 3 Study of NTLA-2001 in ATTRv-PN

NCT06672237 · Intellia Therapeutics

· 2 fields changed

Planned enrollment increased by 10 participants

− Before

50 participants (planned)

+ After

60 participants (planned)

Recruitment status changed

− Before

Active not recruiting

+ After

Recruiting

Check registry source